Vir Biotechnology, Inc. — Form 8-K
Filed July 24, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Item 5.02 filed on 2026-07-24 discloses departure of a director or officer and compensatory arrangements. Specific names, titles, dollar amounts, equity grants, vesting terms, and effective dates are NOT provided in the accessible filing text. Without these concrete details, the materiality and impact cannot be assessed.
Why this rating
Officer/director changes are routine disclosures. No financial impact quantified; lacks specifics to assess materiality relative to $689M market cap.
Extracted items
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.